Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 8/20 | 0.58 |
| ▸ | OPRK1 | P41145 | 8/20 | 0.58 |
| ▸ | NPY4R | P50391 | 9/20 | 0.56 |
| ▸ | NPY5R | Q15761 | 7/20 | 0.56 |
| ▸ | NPY1R | P25929 | 7/20 | 0.56 |
| ▸ | NPY2R | P49146 | 4/20 | 0.54 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.53 |
| ▸ | TFPI | P10646 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29862470 | 0.89 | KISS1R (0.59) | KISS1R | |
| SCHEMBL29862312 | 0.89 | KISS1R (0.59) | KISS1R | |
| SCHEMBL29862114 | 0.89 | KISS1R (0.59) | KISS1R | |
| SCHEMBL29862360 | 0.89 | KISS1R (0.59) | KISS1R | |
| SCHEMBL30605443 | 0.88 | NPY4R (0.54) | OPRM1OPRK1NPY4RNPY5RNPY1R | |
| SCHEMBL30612296 | 0.88 | NPY4R (0.54) | OPRM1OPRK1NPY4RNPY5RNPY1R | |
| SCHEMBL31679104 | 0.87 | NPY4R (0.52) | NPY4RNPY5RNPY1RNPY2RKISS1R | |
| SCHEMBL29862124 | 0.87 | KISS1R (0.58) | KISS1R | |
| SCHEMBL22375041 | 0.87 | IL23R (0.50) | OPRM1OPRK1TFPI | |
| SCHEMBL31207720 | 0.87 | TFPI (0.54) | OPRM1OPRK1NPY4RNPY5RNPY1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9169289-B2 | Peptide derivatives for treatment, prevention or alleviation of a condition associated with bone loss or low bone density or to inhibit osteoclast differentiation and stimulation | STRONGBONE AB (SE) | 2015-10-27 | — | — | US | disclosed |
| US-20140243274-A1 | NOVEL PEPTIDE DERIVATIVES FOR TREATMENT, PREVENTION OR ALLEVIATION OF A CONDITION ASSOCIATED WITH BONE LOSS OR LOW BONE DENSITY OR TO INHIBIT OSTEOCLAST DIFFERENTIATION AND STIMULATION | STRONGBONE AB (SE) | 2014-08-28 | — | — | US | disclosed |
| US-8748370-B2 | Peptide derivatives for treatment, prevention or alleviation of a condition associated with bone loss or low bone density or to inhibit osteoclast differentiation and stimulation | STRONGBONE AB (SE) | 2014-06-10 | — | — | US | disclosed |
| US-20120108515-A1 | NOVEL PEPTIDE DERIVATIVES FOR TREATMENT, PREVENTION OR ALLEVIATION OF A CONDITION ASSOCIATED WITH BONE LOSS OR LOW BONE DENSITY OR TO INHIBIT OSTEOCLAST DIFFERENTIATION AND STIMULATION | NEOBIOTICS AB (SE) | 2012-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108515-A1 | NOVEL PEPTIDE DERIVATIVES FOR TREATMENT, PREVENTION OR ALLEVIATION OF A CONDITION ASSOCIATED WITH BONE LOSS OR LOW BONE DENSITY OR TO INHIBIT OSTEOCLAST DIFFERENTIATION AND STIMULATION | BMP2, SOST, BMP1 | OPRM1 3055/4885OPRK1 2059/4885NPY4R 1014/4885 |
| US-20140243274-A1 | NOVEL PEPTIDE DERIVATIVES FOR TREATMENT, PREVENTION OR ALLEVIATION OF A CONDITION ASSOCIATED WITH BONE LOSS OR LOW BONE DENSITY OR TO INHIBIT OSTEOCLAST DIFFERENTIATION AND STIMULATION | BMP2, CALCRL, ARG1 | OPRM1 1622/4885OPRK1 1155/4885NPY4R 365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.